{
  "source": "PA-Notification-Agamree.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1452-2\nProgram Prior Authorization/Notification\nMedication Agamree® (vamorolone)*\nP&T Approval Date 10/2024\nEffective Date 1/1/2025\n1. Background:\nAgamree (vamorolone)* is a corticosteroid indicated for the treatment of Duchenne muscular\ndystrophy (DMD) in patients 2 years of age and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Agamree* will be approved based on the following criterion:\na. Diagnosis of Duchenne muscular dystrophy\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Agamree* will be approved based on the following criterion:\na. Documentation of positive clinical response to Agamree therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Agamree is typically excluded from coverage. Tried/Failed criteria may be in place. Please\nrefer to plan specifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits, Medical Necessity and/or Step Therapy may be in place.\n4. References:\n1. Agamree [package insert]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc.; June 2024.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Agamree (vamorolone)\nChange Control\n7/2024 New program.\n10/2024 Added exclusion footnote and updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}